Biotechs fight fears of ‘antibiotic apocalypse’

  02 September 2019

Market failure gives little incentive to develop new drugs as antimicrobial resistance grows. 

Carb-X and Repair Impact Fund to fund R&D of novel antibiotics. However, Pharma needs to take over later in the development. 

Further reading: Financial Times
Author(s): Clive Cookson
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Evotec

JSS University





Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!